Loading
A phase 3 trial of Belantamab mafodotin, Pomalidomide, Dexamethasone in multiple myeloma, run by GlaxoSmithKline, active and no longer recruiting.
All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT06956170 by GlaxoSmithKline, with 21 participants enrolled, started 2022-02-10 and due to reach its primary completion in 2024-05-27. Interventions recorded: Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib. Conditions listed: Multiple Myeloma. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
21 enrolled.
The median and upper limit of 95% Confidence Interval were not estimable due to an insufficient number of participants with events within the length of follow-…; Figures from the ClinicalTrials.gov results section (first posted 2025-06-11), not from a publication · 95% CI 1.9 to NA
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-Free Survival (PFS)primary | Belantamab Mafodotin+Pomalidomide+Dexamethasone | 10 | The median and upper limit of 95% Confidence Interval were not estimable due to an insufficient number of participants with events within the length of follow-…; Figures from the ClinicalTrials.gov results section (first posted 2025-06-11), not from a publication | 0.53 (0.1 to 2.78) | - | link |
| Bortezomib + Pomalidomide + Dexamethasone | 11 | 14.8 months |
Shares Belantamab mafodotin, Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, GSK.
Shares Belantamab mafodotin, Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, GSK.
Shares Belantamab mafodotin, Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, GSK.
Shares Belantamab mafodotin, Pomalidomide, Bortezomib, GSK.
Shares Belantamab mafodotin, Antiemetics for chemotherapy-induced nausea and vomiting, GSK, Dexamethasone.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, Dexamethasone.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, Dexamethasone.
Shares Belantamab mafodotin, Pomalidomide, GSK, Dexamethasone.